New drug combo targets brain tumors in early trial
NCT ID NCT03514069
First seen Feb 25, 2026 · Last updated Apr 30, 2026 · Updated 9 times
Summary
This early-phase study tests the safety and best dose of an experimental drug called ruxolitinib when added to standard brain cancer treatment (radiation and temozolomide) for people with newly diagnosed aggressive brain tumors. About 60 adults with grade III gliomas or glioblastoma will take part. The goal is to find a dose that is safe and tolerable.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center
Cleveland, Ohio, 44195, United States
Conditions
Explore the condition pages connected to this study.